去甲斑蝥素对食管癌患者放化疗效果的影响

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (606 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the clinical efficacy of norcantharidin for esophageal cancer patients undergoing radiotherapy and chemotherapy.Methods The clinical data on 68 patients with esophageal cancer treated between May 2015 and February 2017 at Xiangyang Central Hospital was analyzed. The patients were divided into control group and observation group by random number method. Both groups received the same radiotherapy and chemotherapy program, but patients in the observation group were additionally given norcantharidin. The clinical efficacy and safety were reviewed.Results The disease control rate in the observation group(85.29%) was higher than that in control group(73.53%), P<0.05. The incidence of radiation-induced esophagitis in the observation group(47.06%) was lower than that in the control group(79.41%), P<0.05. The dose-limiting toxicity included bone marrow suppression, gastrointestinal symptoms and the damaged liver and kidney function. The incidence of bone marrow suppression and gastrointestinal symptoms was lower than that in the control group, P<0.05.Conclusions Norcantharidin used for treatment of esophageal cancer along with radiotherapy and chemotherapy can enhance clinical efficacy and reduce toxicity.

Key words： norcantharidin esophageal cancer radiation esophagitis adverse reactions

Received: 11 June 2017

ZTFLH:

R453.9

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Yanqing
	LI Changjiang

Cite this article:

WU Yanqing,LI Changjiang. Effect of norcantharidin on radiotherapy and chemotherapy among patients of esophageal cancer[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2018, 29(2): 182-184.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2018/V29/I2/182

[1]	Pennathur A, Gibson M K, Jobe B A, et al. Oesophageal carcinoma[J]. Lancet, 2013, 381(98):400-412.
[2]	Lin D C, Hao J J, Nagata Y, et al. Genomic and molecular characterization of esophageal squamous cell carcinoma[J]. Nat Genet, 2014, 46(5):467-473.
[3]	殷蔚伯,余子豪,徐国镇,等.肿瘤放射治疗学[M].北京:中国协和医科大学出版社,2008:1350-1351.
[4]	曾敏,徐利强,严会志,等. 甘氨双唑钠联合苦参注射液治疗食管癌术后复发患者的临床疗效分析[J].现代生物医学进展,2017,17(3):536-539.
[5]	杜旭艳,苗丽霞,孙岩峰,等.伊立替康联合环磷酰胺治疗晚期神经母细胞瘤疗效观察[J].武警医学,2016, 27(7):714-718.
[6]	朱松明. 紫杉醇联合顺铂化疗方案治疗晚期食道癌的临床疗效观察[J].中国医药导刊,2012,14(12):2160-2161.
[7]	Ma J, Teng H, Wang J, et al. A highly stable norcantharidin loaded lipid microspheres: Preparation, biodistribution and targeting evaluation[J]. Int J Pharm, 2014,473(1/2):475-484.
[8]	Tu G G, Zhan J F, Lv Q L, et al. Synthesis and antiproliferative assay of norcantharidin derivatives in cancer cells[J]. Med Chem, 2014,10(4):376-381.
[9]	潘琪,周强,高志棣,等. 去甲斑蝥素体外抑制NCI-H446细胞迁移、增殖及促进凋亡[J].第三军医大学学报,2011,33(20):2211-2213.
[10]	郑方,郭贺贺,孙志强. 去甲斑蝥素体外抑制骨髓瘤U266细胞增殖的实验研究[J].中国地方病防止杂志,2016,31(8):936.
[11]	原江亮,郑健,毛光华,等. 去甲斑蝥素对人类胆管癌细胞系QBC939增殖和凋亡作用的实验研究[J].肿瘤研究与临床,2011,23(11):768-771.
[12]	姚铠涛,陈江声,陈春莉. 去甲斑蝥素对白血病细胞系K562的增殖、凋亡、细胞周期及NF-κB活性的影响[J].临床肿瘤学杂志,2015,20(5):406-410.
[13]	付盈盈,李林,章激,等. 去甲斑蝥素对非小细胞肺癌模型小鼠免疫功能的影响[J].实用药物与临床,2015,18(6):662-665.

[1]	. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2019, 30(8): 713-715.